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Abstract
Purpose To investigate the incidence and pre-
operative clinical features of reactivated Graves’
orbitopathy (GO) after orbital decompression.
Methods This study included patients with
GO who underwent orbital decompression for
disﬁguring proptosis and not compressive optic
neuropathy and received postoperative follow-
up care for more than 12 months. Patients who
experienced active inﬂammatory signs within
6 months of decompression were excluded from
analysis. The demographic characteristics,
ophthalmic manifestations, and biochemical
parameters of the patients were analyzed for
association with reactivation of GO by logistic
regression analysis.
Results Out of the 92 patients included in this
study, seven (7.6%) experienced reactivation of
GO after orbital decompression. The mean time
interval between surgery and reactivation of
GO was 36.3±14.3 weeks. Univariate logistic
regression analysis identiﬁed age, existing
smoking habits, and modiﬁed NOSPECS and
Gorman scores as signiﬁcant factors for the
reactivation of GO. The results of multivariate
logistic regression analysis revealed that
smoking and modiﬁed NOSPECS and Gorman
scores were associated with the
reactivation of GO.
Conclusions Quitting smoking is important
for the prevention of reactivation of GO after
orbital decompression. Patients with severe
symptoms, especially those with restrictive
myopathy, should be carefully monitored for
reactivation of GO after orbital
decompression.
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Introduction
Graves’ orbitopathy (GO) is an autoimmune
disease associated with Graves’ hyperthyroidism
and affecting the orbital and periorbital tissues.
Although the pathogenesis of GO is not clearly
understood, thyroid-stimulating hormone
receptor (TSH-R) antigen expressed on orbital
ﬁbroblasts and thyroid follicular cells is
considered to be a target co-antigen attacked by
TSH-R antibodies in the blood.1,2 Orbital
ﬁbroblasts may undergo adipogenesis and
produce excessive glycosaminoglycans in
response to immunoglobulin G, a monoclonal
stimulatory TSH-R antibody.3–5 This results in
ocular manifestations of GO, such as proptosis,
conjunctival chemosis, periorbital edema, altered
ocular motility, as well as vision-threatening
compressive optic neuropathy (ON) and
exposure keratitis, all of which bear signiﬁcant
functional, social, and cosmetic consequences.6,7
The natural history of GO is variable.
Classically, an initial active inﬂammatory phase,
lasting 6–24 months, is followed by a chronic
ﬁbrosis phase, as described by Rundle.8
However, GO can sometimes be reactivated after
a certain period of quiescence.9,10 The incidence
of reactivation of GO is not well known, but it
has been reported to range from 5 to 15.7%
depending on the deﬁnition of duration of
inactivity.9,11 Reactivation of GO has been
reported to be associated with periocular
surgery, profound life stress, poorly controlled
hypothyroidism, and smoking.9,12
With the evolution in surgical techniques over
the past few decades, orbital decompression has
come to be performed not only in cases of
compressive ON and exposure keratitis that are
nonresponsive to medical treatment but also in
cases of cosmetic disﬁgurement and orbital
congestion.13,14 Thus, the number of orbital
decompression procedures being performed has
increased over time. However, since there has
been a clinical hypothesis that surgery itself can
activate antigen-presenting cells and orbital
ﬁbroblasts that produce proinﬂammatory
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cytokines,15 the probability of reactivation of GO due to
orbital decompression has also increased. Few studies
have evaluated the reactivation of GO after orbital
decompression. One previous study reported the
incidence rate of this phenomenon as 1.3%; however, such
rate might have been underestimated due to exclusion
of patients who were treated with perioperative
corticosteroids.15 Until now, no study has evaluated the
risk factors or preoperative clinical features associated
with the reactivation of GO after orbital decompression.
In this study, we investigated the short-term incidence
and clinical features of GO in patients who experienced
reactivation of the disease after rehabilitative orbital
decompression surgery.
Subjects and methods
Study design and statement of ethics
This retrospective observational study adhered to the
tenets of the Declaration of Helsinki. Approval for this
study was obtained before the start of study from the
institutional review board of the Severance Hospital,
Yonsei University College of Medicine, South Korea.
Study population
This study included Korean patients with GO who
underwent rehabilitative orbital decompression for the
treatment of disﬁguring proptosis with or without orbital
congestion at the Department of Ophthalmology,
Severance Hospital, Yonsei University College of
Medicine, Seoul, South Korea, between March 2009 and
January 2015. Patients included in the study had
undergone treatment for Graves’ disease (GD) for at least
1 year before surgery, maintained euthyroid status for at
least 3 months before surgery, and received at least
12 months of post-surgical follow-up. Patients who
experienced active inﬂammatory signs after orbital
decompression were identiﬁed. Active inﬂammation was
deﬁned as a CAS≥ 3.
Patients with preoperative compressive optic
neuropathy were excluded. In addition, patients who
exhibited active inﬂammation within 6 months of
decompression were also excluded from analysis, since
the active phase in such cases could be considered as
a continuation of the preoperative inﬂammatory
processes.11
Clinical and biochemical variables
We reviewed the results of clinical ophthalmic
examination including evaluation of best-corrected visual
acuity and intraocular pressure, exophthalmometric
measurements performed with a Hertel
exophthalmometer, Hess screen test, binocular single-
vision test, and pre- and post-operative computed
tomography (CT). We also recorded durations of GD and
GO before surgery.
Patients who still had a smoking habit at the time of
surgery were considered smokers. Severity of GO was
quantiﬁed using a modiﬁed NOSPECS score,16 which
involved grading of the following parameters: lid
retraction (class 1, score 0–1), soft-tissue inﬂammation
(class 2, score 0–3), proptosis (class 3, score 0–3),
myopathy (class 4, score 0–3), corneal defect (class 5, score
0–1), and ON (class 6, 0 or 3). The sum of the scores
constituted the modiﬁed NOSPECS score (range, 0–14).
The Gorman score was used to evaluate the severity of
diplopia: no diplopia (1), intermittent diplopia (2), gaze-
evoked diplopia (3), and constant diplopia in the primary
position (4).17 Activity of GO was assessed according to
the seven-point clinical activity scoring system described
by Mourits et al.18
Biochemical parameters, including free T4, thyroid
stimulating hormone (TSH), thyrotropin-binding
inhibitor immunoglobulin (TBII), and thyroid-stimulating
immunoglobulin (TSI) concentrations, were measured
within 4 weeks before surgery. Thyrotropin-binding
inhibitor immunoglobulin levels were measured by an
M22-TSH-receptor antibody (TRAb) assay using the
automated Cobas electrochemiluminescence system
(Elecsys, Roche Diagnostics GmbH, Penzberg, Germany)
according to the manufacturer’s instructions. The cutoff
value for positive result using this system was
1.75 IU/L.19 Thyroid-stimulating immunoglobulin levels
in patient sera were measured using the Mc4-based
Thyretain TSI Reporter BioAssay (Diagnostic Hybrids,
Inc., Athens, OH, USA) kit according to the
manufacturer’s instructions. The cutoff value for positive
results using this system was 140 specimen-to-reference
ratio (SRR)%.
Surgical techniques and postoperative management
A single surgeon (JSY) conducted orbital decompression
surgery in all patients. Surgery was performed through a
lower canthofornix and caruncle approach under general
anesthesia, as previously reported.20 Following septal
incision, all postseptal medial, central, and lateral fat pads
were excised. The retrobulbar inferolateral fat pocket,
which has the greatest amount of fat, was dissected
between the lateral and inferior rectus muscles, incising
the tenon fascia towards the apex. In the same manner,
maximal amounts of inferomedial and caruncular fat
tissues were removed carefully to avoid damage to the
inferior rectus, inferior oblique, and medial rectus muscles
until satisfactory reduction of proptosis was achieved.
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If fat decompression alone was insufﬁcient for proptosis
reduction, additional decompression of the posterior
ethmoid bone and/or posterior ﬂoor, mostly involving
the posterior strut, was performed. In patients with
prominent muscle enlargement, bony wall decompression
to release venous congestion was always performed along
with the excision of orbital fat tissues.
Patients were routinely administered corticosteroids at
a dose of 125 mg of on the day of surgery, followed by 15
and 5 mg doses in the ﬁrst and second weeks after
surgery, respectively.
Statistical analysis
Statistical analysis was performed using the SPSS
software (Version 20.0 for Windows, SPSS, Inc., Chicago,
IL, USA). The normality of data distribution was
evaluated using the Kolmogorov–Smirnov test.
Univariate logistic regression analyses were performed to
identify clinical factors related to reactivation of GO after
orbital decompression. Multivariate logistic regression
analyses were subsequently performed to determine
whether variables revealed as signiﬁcant in the univariate
model were independently associated with reactivation of
GO after surgery. Results were considered statistically
signiﬁcant at P-valueso0.05.
Results
A total of 92 patients underwent orbital decompression
for the treatment of disﬁguring proptosis within the study
period. The mean duration of post-surgical follow-up was
2.9± 1.3 years (range, 1.0–6.0 years). The demographic
and clinical features of the included patients are described
in Table 1. Out of the 92 patients, seven (7.6%)
experienced reactivation of GO after orbital
decompression. The demographics, types of orbital
decompression, as well as pre- and post-operative clinical
characteristics of these patients are summarized in
Table 2. All of these patients exhibited CAS ≤ 1 within
2 weeks of orbital decompression (Figure 1). The mean
value of Hertel exophthalmometric measurement of the
severely affected eye decreased from 21.6± 1.4 mm before
surgery to 17.3± 1.5 mm post surgery (P= 0.018). Active
signs and symptoms of GO developed at a mean interval
of 36.3± 14.3 weeks (median, 32; range, 26–68, weeks)
after surgery. At the point of reactivation, four were
identiﬁed as euthyroid, two as hyperthyroid, and one as
hypothyroid. TBII (9.95 IU/l) showed no signiﬁcant
increase (P= 0.753) in measurement, whereas TSI level
(594.5 SRR%) increased signiﬁcantly (P= 0.043) at
reactivation compared with its level at preoperative
status. Out of the seven patients, ﬁve were treated for
active inﬂammation with parenteral corticosteroids, one
with orbital irradiation (2 Gy× 10 sessions), and one with
both modalities. All patients were responsive to
treatment.
Univariate and multivariate analysis
Table 3 presents possible preoperative factors affecting the
reactivation of GO after orbital decompression, as
determined by univariate logistic regression analyses. Age,
smoking habits, and modiﬁed NOSPECS and Gorman
scores were statistically signiﬁcant positive factors related
to the reactivation of GO after orbital decompression. The
differences in preoperative durations of GO and GD, CAS,
and biochemical variables including TBII and TSI levels
between patients with or without reactivation of GO after
surgery were not statistically signiﬁcant.
In the multivariate model, age, sex, and factors
identiﬁed in univariate analysis as signiﬁcantly affecting
the reactivation of GO after orbital decompression were
used as independent variables to exclude the inﬂuence of
confounding factors. Since the modiﬁed NOSPECS and
Gorman scores are correlated, either one (model 1 and 2,
respectively), but not both, was used as a variable in the
multivariate model. The results of multivariate logistic
regression analysis revealed smoking habits (odds ratio
[OR], 11.291; 95% conﬁdence interval (CI), 1.033–123.369
in model 1; OR, 41.315; 95% CI, 1.231–386.900 in model 2),
modiﬁed NOSPECS scores (OR, 2.112; 95% CI, 1.111–
4.016 in model 1), and Gorman scores (OR, 8.508; 95% CI,
1.033–68.561 in model 2) as being signiﬁcant positive,
independent factors related to reactivation of GO after
orbital decompression (Table 4).
Table 1 Demographic and clinical characteristics of patients
who underwent orbital decompression (N= 92)
Variable, unit Value
Age, years 36.5± 13.3
Male, n (%) 22 (23.9)
Current smoker, n (%) 19 (20.7)
GO symptom duration, months 40.7± 46.2
GD symptom duration, months 47.3± 55.1
Clinical activity score 1.2± 0.9
Modiﬁed NOSPECS score 4.7± 1.9
Restrictive myopathy, n (%) 25 (27.2)
Exophthalmos of severe eye, mm 21.4± 2.7
Free T4, ng/ml 1.2± 0.3
TSH, mU/l 1.4± 2.0
TBII, IU/l 9.2± 12.3
TSI, SRR% 315.1± 144.7
Abbreviations: GD, Graves’ disease; GO, Graves’ orbitopathy; SRR,
specimen-to-reference ratio; TBII, thyrotropin-binding inhibitor immuno-
globulin; TSH, thyroid stimulating hormone; TSI, thyroid-stimulating
immunoglobulin.
Data are expressed as mean± standard deviation or number (percentage).
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Table 2 Clinical characteristics of patients with reactivation of GO after orbital decompression
No. Sex Age
(years)
Pre-op
CAS
Type of orbital
decompression
Duration of
inactivity after
surgery
(months)
Thyroid status
at reactivation
CAS at
reactivation
TSI at
reactivation
(SRR%)
Duration of
reactivation
(months)
Treatment of
reactivation
1 Female 58 2 Fat, bony (inf, med) 28 Hyperthyroid 5 743.8 9 IV steroid
2 Female 51 2 Fat, bony (inf, med) 32 Euthyroid 4 509.3 6 IV steroid, RT
3 Male 59 2 Fat, bony (med) 68 Euthyroid 4 574.0 10 RT
4 Male 47 3 Fat, bony (inf, med) 36 Euthyroid 3 728.7 6 IV steroid
5 Male 42 1 Fat, bony (inf, med) 26 Euthyroid 4 359.5 9 IV steroid
6 Female 52 1 Fat 32 Hypothyroid 4 675.5 5 IV steroid
7 Female 45 2 Fat, bony (inf, med) 32 Hyperthyroid 4 630.9 8 IV steroid
Abbreviations: CAS, clinical activity score; inf, inferior orbital wall; IV, intravenous; med, medial orbital wall; RT, radiation therapy; SRR, specimen-to-
reference ratio; TSI, thyroid-stimulating immunoglobulin.
Figure 1 Preoperative (left column) and 2 weeks postoperative (right column) photographs of patients who underwent orbital
decompression. (a) Patient numbered 4 in Table 2. (b) Patient numbered 7 in Table 2.
Table 3 Univariate logistic regression analysis of various parameters in association with reactivation of GO after orbital decompression
Reactivaion (− ) Reactivaion (+) Exp(B) 95% CI P-value
Number 85 7
Age, years 35.2±13.0 50.6± 6.4 1.085 1.020–1.154 0.010
Male gender, n (%) 18 (21.2) 3 (42.9) 0.421 0.086–2.061 0.286
Smoker, n (%) 13 (15.3) 5 (71.4) 11.923 2.081–68.299 0.005
GO symptom duration, months 40.1± 41.9 47.9± 84.8 1.003 0.989–1.018 0.670
GD symptom duration, months 46.4± 48.7 56.6± 107.5 1.003 0.991–1.015 0.642
Clinical activity score 1.2± 0.9 1.9± 0.7 2.317 0.898–5.979 0.082
Modiﬁed NOSPECS score 4.4± 1.7 7.9± 2.1 2.329 1.395–3.888 0.001
Gorman score 1.4± 0.8 2.9± 0.4 4.828 1.769–13.176 0.002
Exophthalmos of severe eye, mm 21.4± 2.7 21.6± 1.4 1.022 0.765–1.364 0.884
Free T4, ng/ml 1.2± 0.3 1.2± 0.5 1.178 0.082–17.023 0.904
TSH, mU/l 1.4± 2.0 1.3± 1.6 0.972 0.643–1.470 0.895
TBII, IU/l 9.3± 12.7 7.2± 6.3 0.984 0.908–1.066 0.688
TSI, SRR% 303.3± 136.3 399.5± 194.3 1.005 0.999–1.010 0.103
Abbreviations: CI, conﬁdence interval; Exp(B), odds; GO, Graves’ orbitopathy; GD, Graves’ disease; SRR, specimen-to-reference ratio; TBII;
thyrotropin-binding inhibitor immunoglobulin; TSH, thyroid stimulating hormone; TSI, thyroid-stimulating immunoglobulin.
Bold characters refer to statistical signiﬁcance (Po0.05).
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Discussion
This study investigated the short-term incidence and
preoperative clinical features of reactivated GO after
rehabilitative orbital decompression. Out of the 92
patients with GO included in this study, seven (7.6%)
experienced reactivation of GO after orbital
decompression, with a mean quiescence period of
36.3± 14.3 weeks. Our results indicated that smoking
habits and severe ophthalmic symptoms, especially
myopathy, were preoperative factors contributing to the
reactivation of GO after surgery.
Reactivation of GO is not a common phenomenon and
has, therefore, been poorly documented.9 Its incidence is
not well established and could vary depending on the
deﬁnition of period of inactivity.9,11 Selva et al determined
the late recurrence rate to be 5%, based on their deﬁnition
of reactivation as recurrence of inﬂammation after
5 years of inactivity.9 More recently, recurrence of active
inﬂammation after 6 months of inactivity has been
deﬁned as reactivation of GO, since a majority of
clinicians deﬁne the stable phase of GO for orbital
decompression as a quiescence period of 6 months.
On the basis of this recent deﬁnition of recurrence, Patel
et al reported the incidence of reactivation of GO as
15.7%.11
Reactivation of GO after orbital decompression has
been also rarely reported. Baldeschi et al reported three
such cases among 239 patients (1.3%) who underwent
rehabilitative orbital decompression and described the
condition as delayed decompression-related
reactivation.15 However, the reported incidence might
have been underestimated because the authors excluded
patients who received perioperative corticosteroid
treatment, in order to examine the natural course and
unaffected clinical manifestation of delayed
decompression-related reactivation. In the present study,
patients who received perioperative corticosteroid
treatment were also included. They were administered
corticosteroids for 2 weeks in the same manner as the rest
of the included patients, in order to prevent post-operative
edema around the operation site. The incidence of
reactivation of GO after orbital decompression observed
in the present study (7/92 patients; 7.6%) was slightly
higher compared with that reported by Baldeschi et al15
(5.9% (14/239), including 11 patients who received
perioperative corticosteroid treatment).
In general, many clinicians have used CAS to evaluate
disease activity in GO. Such application was ﬁrst
introduced by Mourits et al18 in 1989, in attempts to
distinguish active GO patients who respond to
corticosteroid treatment. However, despite the increasing
use of CAS in clinical ofﬁces, it does not always represent
real GO activity. For example, although patients with
long standing orbital congestion have high CAS, they are
only responsive to mechanical decompression and not
corticosteroid treatment.12 In addition, sometimes,
postoperative inﬂammatory reaction cannot be
distinguishable to disease activity of GO after orbital
decompression when it assessed with CAS. In such cases,
short-term postoperative corticosteroid administration
can help with the selection process, since inﬂammation
will arise again after corticosteroid tapering in real active
phase of GO, and not in just postoperative inﬂammatory
reaction. In the cases we observed, postoperative
inﬂammatory reaction subsided with corticosteroid
administration, and did not arise after corticosteroid
cessation. The resulting CAS decreased after orbital
decompression, due to resolution of orbital congestion
and corticosteroid administration.
The average interval of inactivity between orbital
decompression and reactivation in the present study was
36.3± 14.3 weeks (range, 26–68 weeks). The mean interval
between the appearance of the ﬁrst symptom of GO and
reactivation of GO observed in our study (4.7 years) was
shorter compared with that reported by Patel et al11 (10.3
years; range, 2–56 years). Although the short duration of
follow-up could have affected the results of the present
study, we considered immune reaction triggered by
orbital decompression to be the main reason for early
reactivation. Surgical trauma could activate antigen-
presenting cells and orbital ﬁbroblasts that produce
proinﬂammatory cytokines, including interleukin-2,
interferon gamma, and tumor necrosis factors. In
addition, exposure of orbital tissue to exogenous
pathogens or endogenous normal ﬂora also could induce
inﬂammation.15
Smoking is a well-known risk factor for GO. A previous
case–control study reported an OR of 7.7 for the
association between smoking and incidence of GO.21
Table 4 Multivariate logistic regression analysis of various
parameters for predicting reactivation of GO after orbital
decompression
Independent variable Exp(B) Standard error P-value
Model 1
Age 1.042 0.049 0.403
Gender 1.093 1.210 0.941
Current smoker 11.291 1.220 0.047
Modiﬁed NOSPECS 2.112 0.328 0.023
Model 2
Age 1.073 0.056 0.206
Gender 12.091 1.633 0.127
Current smoker 41.315 1.793 0.038
Gorman score 8.508 1.065 0.044
Abbreviations: CAS, clinical activity score; Exp(B), odds.
Bold characters refer to statistical signiﬁcance (Po0.05).
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The severity of GO in smokers tends to be greater
compared with that in nonsmokers.22 Smoking accelerates
the progression of GO after radioiodine therapy and
decreases the effect of corticosteroid or orbital irradiation
therapy.23 In the present study, patients with a smoking
habit at the time of surgery were considered smokers. Our
results indicated that smoking was a positive and
independent factor for the reactivation of GO after orbital
decompression, with ORs of 11.291 (model 1) and 41.315
(model 2), which were higher compared with that
reported in a previous cohort study without surgery.21
Therefore, in case of patients who are expected to
undergo orbital decompression, discontinuation of
smoking is important for the prevention of reactivation
after surgery.
On the basis of clinical features, two different
phenotypes of GO have been described—type I with
predominant retrobulbar fat proliferation and type II with
predominant extraocular muscle enlargement.24 Patients
with type I GO usually present with symmetric proptosis
with minimal or no diplopia, whereas those with type II
GO often exhibit diplopia with restrictive myopathy. The
reason behind the differential involvement of orbital fat
and extraocular muscle in GO has thus far not been well
deﬁned. In a previous in vitro study, orbital ﬁbroblasts
were revealed as playing a certain role in the pathogenesis
of both subtypes of GO, interacting with cytokines,
prostaglandins, and immune cells.25 In the present study,
preoperative Gorman diplopia score was revealed to be
a signiﬁcant factor for reactivation of GO after orbital
decompression. In other words, the degree of
preoperative restrictive myopathy is associated with the
postoperative reactivation of GO. This ﬁnding is
supported by those of Nunery et al,24 who suggested that
type II GO might cause orbital inﬂammation more
frequently than type I GO. In general, orbital
decompression decreases orbital tissue pressure and
improves orbital congestive conditions. In addition,
removal of orbital fat tissues containing ﬁbrocytes and
auto-reactive lymphocytes decreases the production of
inﬂammatory cytokines.26,27 However, the presence of an
antigenic component of muscle tissue that was not
removed during orbital decompression was thought to be
a possible reason for immune response despite the anti-
inﬂammatory effect of the surgery.28
Because of the retrospective study design and the small
number of patients with reactivated GO, a major
limitation of this study is the interpretation of collected
data. Since this was not a comparative controlled study,
our ﬁndings are subject to the potential inﬂuence of
factors that were not evaluated in this study. In addition,
our mean follow-up duration (2.9± 1.3 years) was
relatively short. Further studies with longer durations of
follow-up are required for the evaluation of late-onset
reactivation of GO. Also, in order to determine whether or
not orbital decompression affects GO reactivation in
patients with restrictive myopathy, further case-control
study comparing decompressed and non-decompressed
GO patients would be needed.
Our results indicate that reactivation of GO after orbital
decompression tends to occur in patients who experience
severe preoperative ophthalmic symptoms, especially
restrictive myopathy. In addition, smoking status at the
time of surgery is a signiﬁcant positive, independent
factor for reactivation of GO after orbital decompression.
Patients presenting with these factors should be carefully
monitored for reactivation of GO even if it is observed to
be inactive after orbital decompression. Especially, since
smoking is a modiﬁable risk factor, patients should quit
smoking before undergoing orbital decompression.
Further investigation of the inﬂammatory mechanisms of
GO and prospective controlled studies including large
numbers of patients are required.
Summary
What was known before
K Reactivation of Graves' orbitopathy is not common
phenomenon but periocular surgery including orbital
decompression is associated with reactivation of Graves'
orbitopathy.
What this study adds
K A smoking habit and restrictive myopathy are
contributing factors to the reactivation of Graves'
orbitopathy after orbital decompression.
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